IDBiologics
Nashville
About IDBiologics
IDBiologics was founded in 2017 to discover and develop human monoclonal antibodies for the prevention, treatment, and cure of infectious diseases.Their innovative fully human monoclonal antibody platform enables rapid discovery and optimization of broad and potent therapeutic molecules.Using this proprietary platform, IDBiologics has accumulated unparalleled breadth in isolating antibodies for infectious diseases, with lead candidate molecules to diverse targets moving forward in development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.8M
- Funding stage: Seed
- Last round: Seed (May 2023)
- Website: idbiologics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Therapeutics
Canonical: https://fsome.com/organization/idbiologics-138527 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.